Gilead Sciences (GILD) EBITDA Margin Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBITDA Margin Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
57.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
660.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-179.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-138.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-6,345.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
1,648.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
360.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
2,760.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
437.00 |
| 10 |
Novartis Ag |
109.78 Bn |
109.09 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
360.00 |
| Dec 31, 2025 |
-736.00 |
| Sep 30, 2025 |
3,105.00 |
| Jun 30, 2025 |
-309.00 |
| Mar 31, 2025 |
9,820.00 |
| Dec 31, 2024 |
974.00 |
| Sep 30, 2024 |
-2,543.00 |
| Jun 30, 2024 |
1,279.00 |
| Mar 31, 2024 |
-9,148.00 |
| Dec 31, 2023 |
-802.00 |
| Sep 30, 2023 |
-309.00 |
| Jun 30, 2023 |
-718.00 |
| Mar 31, 2023 |
2,385.00 |
| Dec 31, 2022 |
1,770.00 |
| Sep 30, 2022 |
-1,149.00 |
| Jun 30, 2022 |
-371.00 |
| Mar 31, 2022 |
-4,201.00 |
| Dec 31, 2021 |
-2,275.00 |
| Sep 30, 2021 |
2,135.00 |
| Jun 30, 2021 |
9,413.00 |
